Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia

Translated title of the contribution: The cost of illness of failed back surgery syndrome for patients eligible for spinal cord stimulation in Italy

F. Zucco, R. Ravasio, A. Lavano, M. de Rose, P. Poli, G. Fortini, L. Demartini, E. de Simone, V. Menardo, P. Cisotto, M. Meglio, A. Costantini

Research output: Contribution to journalArticle

Abstract

Objective: To assess the costs and clinical condition of Failed Back Surgery Syndrome (FBSS) for patients eligible for Spinal Cord Stimulation (SCS) in Italy. Methods: A multicentre, retrospective data collection with a maximum time horizon of 12 months was developed. Nine Italian Centers experienced in SCS were involved enrolling 80 patients. Use and costs of healthcare and non-healthcare resources, clinical condition and HR-QoL data were collected through specific questionnaires submitted to patients. Mean monthly costs (EUR 2008) were evaluated according to three perspectives: Patient, National Healthcare System (NHS) and Society. Results: A strong impairment in baseline HR-QoL was documented. Mean utility score was 0.07 (general UK population: 0.70). According to the Oswestry questionnaire, 44% of patients were crippled and 39% severely disabled. All SF-36 dimensions were worse than in normal population. To treat FBSS, monthly expenditure per patient was equal to €177.34, €221.12 and €1,046.12 from the perspectives of Patient, NHS and Society, respectively. Productivity losses accounted for 62% of the societal total costs, while hospitalizations explained 28% of the costs sustained by the NHS. From the patient perspective, themain cost drivers were home care (27%) and travel expenses (26%). Conclusions: This Cost-of-Illness analysis confirms FBSS as a disabling and costly disease.

Original languageItalian
Pages (from-to)29-42
Number of pages14
JournalPharmacoEconomics - Italian Research Articles
Volume13
Issue number1
Publication statusPublished - 2011

Fingerprint

Failed Back Surgery Syndrome
Spinal Cord Stimulation
Cost of Illness
Italy
Costs and Cost Analysis
Delivery of Health Care
Home Care Services
Health Expenditures
Health Care Costs
Population
Hospitalization

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia. / Zucco, F.; Ravasio, R.; Lavano, A.; de Rose, M.; Poli, P.; Fortini, G.; Demartini, L.; de Simone, E.; Menardo, V.; Cisotto, P.; Meglio, M.; Costantini, A.

In: PharmacoEconomics - Italian Research Articles, Vol. 13, No. 1, 2011, p. 29-42.

Research output: Contribution to journalArticle

Zucco, F, Ravasio, R, Lavano, A, de Rose, M, Poli, P, Fortini, G, Demartini, L, de Simone, E, Menardo, V, Cisotto, P, Meglio, M & Costantini, A 2011, 'Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia', PharmacoEconomics - Italian Research Articles, vol. 13, no. 1, pp. 29-42.
Zucco, F. ; Ravasio, R. ; Lavano, A. ; de Rose, M. ; Poli, P. ; Fortini, G. ; Demartini, L. ; de Simone, E. ; Menardo, V. ; Cisotto, P. ; Meglio, M. ; Costantini, A. / Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia. In: PharmacoEconomics - Italian Research Articles. 2011 ; Vol. 13, No. 1. pp. 29-42.
@article{c2d0b9bf4be64ac3a32bf330747dd24b,
title = "Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia",
abstract = "Objective: To assess the costs and clinical condition of Failed Back Surgery Syndrome (FBSS) for patients eligible for Spinal Cord Stimulation (SCS) in Italy. Methods: A multicentre, retrospective data collection with a maximum time horizon of 12 months was developed. Nine Italian Centers experienced in SCS were involved enrolling 80 patients. Use and costs of healthcare and non-healthcare resources, clinical condition and HR-QoL data were collected through specific questionnaires submitted to patients. Mean monthly costs (EUR 2008) were evaluated according to three perspectives: Patient, National Healthcare System (NHS) and Society. Results: A strong impairment in baseline HR-QoL was documented. Mean utility score was 0.07 (general UK population: 0.70). According to the Oswestry questionnaire, 44{\%} of patients were crippled and 39{\%} severely disabled. All SF-36 dimensions were worse than in normal population. To treat FBSS, monthly expenditure per patient was equal to €177.34, €221.12 and €1,046.12 from the perspectives of Patient, NHS and Society, respectively. Productivity losses accounted for 62{\%} of the societal total costs, while hospitalizations explained 28{\%} of the costs sustained by the NHS. From the patient perspective, themain cost drivers were home care (27{\%}) and travel expenses (26{\%}). Conclusions: This Cost-of-Illness analysis confirms FBSS as a disabling and costly disease.",
author = "F. Zucco and R. Ravasio and A. Lavano and {de Rose}, M. and P. Poli and G. Fortini and L. Demartini and {de Simone}, E. and V. Menardo and P. Cisotto and M. Meglio and A. Costantini",
year = "2011",
language = "Italian",
volume = "13",
pages = "29--42",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Il costo della sindrome da fallimento chirurgico spinale (failed back surgery syndrome, FBSS) nei pazienti con indicazione a impianto per neurostimolazione midollare in Italia

AU - Zucco, F.

AU - Ravasio, R.

AU - Lavano, A.

AU - de Rose, M.

AU - Poli, P.

AU - Fortini, G.

AU - Demartini, L.

AU - de Simone, E.

AU - Menardo, V.

AU - Cisotto, P.

AU - Meglio, M.

AU - Costantini, A.

PY - 2011

Y1 - 2011

N2 - Objective: To assess the costs and clinical condition of Failed Back Surgery Syndrome (FBSS) for patients eligible for Spinal Cord Stimulation (SCS) in Italy. Methods: A multicentre, retrospective data collection with a maximum time horizon of 12 months was developed. Nine Italian Centers experienced in SCS were involved enrolling 80 patients. Use and costs of healthcare and non-healthcare resources, clinical condition and HR-QoL data were collected through specific questionnaires submitted to patients. Mean monthly costs (EUR 2008) were evaluated according to three perspectives: Patient, National Healthcare System (NHS) and Society. Results: A strong impairment in baseline HR-QoL was documented. Mean utility score was 0.07 (general UK population: 0.70). According to the Oswestry questionnaire, 44% of patients were crippled and 39% severely disabled. All SF-36 dimensions were worse than in normal population. To treat FBSS, monthly expenditure per patient was equal to €177.34, €221.12 and €1,046.12 from the perspectives of Patient, NHS and Society, respectively. Productivity losses accounted for 62% of the societal total costs, while hospitalizations explained 28% of the costs sustained by the NHS. From the patient perspective, themain cost drivers were home care (27%) and travel expenses (26%). Conclusions: This Cost-of-Illness analysis confirms FBSS as a disabling and costly disease.

AB - Objective: To assess the costs and clinical condition of Failed Back Surgery Syndrome (FBSS) for patients eligible for Spinal Cord Stimulation (SCS) in Italy. Methods: A multicentre, retrospective data collection with a maximum time horizon of 12 months was developed. Nine Italian Centers experienced in SCS were involved enrolling 80 patients. Use and costs of healthcare and non-healthcare resources, clinical condition and HR-QoL data were collected through specific questionnaires submitted to patients. Mean monthly costs (EUR 2008) were evaluated according to three perspectives: Patient, National Healthcare System (NHS) and Society. Results: A strong impairment in baseline HR-QoL was documented. Mean utility score was 0.07 (general UK population: 0.70). According to the Oswestry questionnaire, 44% of patients were crippled and 39% severely disabled. All SF-36 dimensions were worse than in normal population. To treat FBSS, monthly expenditure per patient was equal to €177.34, €221.12 and €1,046.12 from the perspectives of Patient, NHS and Society, respectively. Productivity losses accounted for 62% of the societal total costs, while hospitalizations explained 28% of the costs sustained by the NHS. From the patient perspective, themain cost drivers were home care (27%) and travel expenses (26%). Conclusions: This Cost-of-Illness analysis confirms FBSS as a disabling and costly disease.

UR - http://www.scopus.com/inward/record.url?scp=79957969032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957969032&partnerID=8YFLogxK

M3 - Articolo

VL - 13

SP - 29

EP - 42

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 1

ER -